Dirk Thye, Quince Therapeutics CEO
April 11, 2023 07:34 AM EDT
People

Af­ter set­ting up poi­son pill, Quince Ther­a­peu­tics board gives flat-out re­jec­tion to un­so­licit­ed buy­er

Kyle LaHucik

Senior Reporter

In a terse state­ment Tues­day morn­ing, Quince Ther­a­peu­tics said its board “unan­i­mous­ly re­ject­ed” the un­so­licit­ed pro­pos­al from Echo Lake Cap­i­tal and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times